Wyeth Explains Prevnar Allocation System
In a Feb. 12 1letter to practitioners, Wyeth explained its plans for allocating supplies of the pneumococcal conjugate vaccine Prevnar until manufacturing delays are resolved. The allocation program is based on monthly purchase history and reflects updated recommendations by CDC on delaying administration of the fourth dose in the series (2"The Pink Sheet" Feb. 16, 2004, p. 20).
You may also be interested in...
Wyeth's Prevnar allocation program will run until at least mid-July, with shipments to providers cut by 20%
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials